Semler Scientific Q3 2023 Earnings Report

Semler Scientific reported increased revenue and net income for Q3 2023.

Key Takeaways

Semler Scientific reported a 16% increase in revenue and a 50% increase in net income for the third quarter of 2023, driven by sales of QuantaFlo® for peripheral arterial disease testing. The company is focused on expanding its business in support of the diagnosis of heart dysfunction.

Revenue of $16.3 million, an increase of 16% compared to the corresponding period of 2022

Net income of $5.5 million, an increase of 50% compared to the corresponding period of 2022

Quarter-ending cash, cash equivalents and short-term investments of $56.0 million

Pre-tax net income of $7.0 million, an increase of $2.4 million, or 52%, compared to $4.6 million.